title: NICE is likely to reject bevacizumab for bowel cancer.
authors.forename: Caroline
authors.initials: C
authors.lastname: White
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004739:England; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D014852:Wales
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab